ATE276364T1 - Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren - Google Patents

Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren

Info

Publication number
ATE276364T1
ATE276364T1 AT99950801T AT99950801T ATE276364T1 AT E276364 T1 ATE276364 T1 AT E276364T1 AT 99950801 T AT99950801 T AT 99950801T AT 99950801 T AT99950801 T AT 99950801T AT E276364 T1 ATE276364 T1 AT E276364T1
Authority
AT
Austria
Prior art keywords
gene
pharmaceutical compositions
biological material
cell
mammals
Prior art date
Application number
AT99950801T
Other languages
English (en)
Inventor
Bruce Acres
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE276364T1 publication Critical patent/ATE276364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT99950801T 1998-10-22 1999-10-20 Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren ATE276364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9813279A FR2784997A1 (fr) 1998-10-22 1998-10-22 Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
PCT/FR1999/002551 WO2000024896A2 (fr) 1998-10-22 1999-10-20 Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes

Publications (1)

Publication Number Publication Date
ATE276364T1 true ATE276364T1 (de) 2004-10-15

Family

ID=9531887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950801T ATE276364T1 (de) 1998-10-22 1999-10-20 Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren

Country Status (12)

Country Link
US (1) US20050221435A1 (de)
EP (1) EP1084246B1 (de)
JP (1) JP2002528466A (de)
AT (1) ATE276364T1 (de)
AU (1) AU754505C (de)
CA (1) CA2344207A1 (de)
DE (1) DE69920216T2 (de)
DK (1) DK1084246T3 (de)
ES (1) ES2228115T3 (de)
FR (1) FR2784997A1 (de)
PT (1) PT1084246E (de)
WO (1) WO2000024896A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142885A1 (en) * 2001-01-26 2004-07-22 Stephane Paul Biological organism for preparing pharmaceutical compositions for treating mammals
US20040177016A1 (en) * 2002-09-30 2004-09-09 Jones Emerson P. Method and system for analyzing a capital structure for a company
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2758569B1 (fr) * 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant

Also Published As

Publication number Publication date
DE69920216D1 (de) 2004-10-21
US20050221435A1 (en) 2005-10-06
AU754505B2 (en) 2002-11-21
ES2228115T3 (es) 2005-04-01
AU754505C (en) 2003-12-04
JP2002528466A (ja) 2002-09-03
WO2000024896A3 (fr) 2000-08-03
DE69920216T2 (de) 2005-09-22
PT1084246E (pt) 2005-02-28
AU6344499A (en) 2000-05-15
EP1084246B1 (de) 2004-09-15
EP1084246A2 (de) 2001-03-21
FR2784997A1 (fr) 2000-04-28
WO2000024896A2 (fr) 2000-05-04
CA2344207A1 (fr) 2000-05-04
DK1084246T3 (da) 2005-01-31

Similar Documents

Publication Publication Date Title
Mülling et al. How structures in bovine hoof epidermis are influenced by nutritional factors.
NO820090L (no) Fremgangsmaate for fremstilling og behandling av renninderivater
ES8505724A1 (es) Procedimiento para la produccion de polipetidos mediante levadura.
DK720488D0 (da) Immunokompromitterede kimaerepattedyr og anvendelse heraf til fremstilling af celler og stoffer
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
JPS5970620A (ja) 均質なヒトインタ−ロイキン２及びその製造方法
DE59912118D1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
ATE276364T1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
Mahmoudi et al. An Elastin‐Derived Composite Matrix for Enhanced Vascularized and Innervated Bone Tissue Reconstruction: From Material Development to Preclinical Evaluation
KR970706838A (ko) 조혈 단백질을 사용한 적혈구생성을 자극하는 방법(methods for stimulating erythropoiesis using hematopoietic proteins)
DE3752391D1 (de) Rattenproteinkinase C und Verfahren zur Herstellung
Dao et al. Molecular control of cell cycle progression in primary human hematopoietic stem cells: methods to increase levels of retroviral-mediated transduction
ATE80912T1 (de) Menschliche proteine des chinolinesterase-typs und ihre herstellung.
DE69837380D1 (de) Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
Edwards et al. Divergence of β-Myosin Heavy Chain (βMHC) Expression in Fetal Rat Cardiomyocytesin Vitroand Adult Rat Heartin Vivo
ATE260339T1 (de) Antikörper gegen menschliches restrictin
KR970015600A (ko) Atp-민감성의 새로운 칼륨-통로 단백질과 그의 유전자
US8323963B2 (en) Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
JPH07501695A (ja) Ｉｆｎ‐ガンマ‐アンタゴニストサイトカイン
US20030077758A1 (en) Myc repressor modulation to treat aging-related disorders
EP1220873A1 (de) Neue proteinkomponente und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1084246

Country of ref document: EP

REN Ceased due to non-payment of the annual fee